Novel Fibromyalgia Treatment Shows Promise in Study
TUSCALOOSA, Ala. and BOSTON, Nov. 18, sun2014 /PRNewswire/ -- A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.
Detailed results of the randomized, double-blinded, placebo-controlled Phase II study, known as PRID-201, were presented today at the 2014 American College of Rheumatology annual meeting in Boston by William L. Pridgen, M.D., FACS, founder and CEO of Innovative Med Concepts.
According to Daniel J. Clauw, M.D., director of the Chronic Pain & Fatigue Research Center at the University of Michigan (Ann Arbor), commenting on the PRID-201 results, "IMC-1 shows promise as a potentially new treatment for the millions of people who suffer from this debilitating condition."
Fibromyalgia is a multi-symptom disorder involving widespread pain, fatigue, headaches, sleep problems, mood changes and inability to concentrate. Its causes are unknown. According to the National Fibromyalgia Association, an estimated 3-6 percent of people worldwide suffer from the condition—10 million people in the United States alone.(nog even de prevalentie gehighlight, zit ik met mijn 1% toch echt niet zo gek hoor. red.)
....
"Many herpes viruses are known to significantly upregulate COX enzymes in the body, which in turn are important for efficient viral replication," Pridgen said. "In theory, physical or emotional stress in patients can reactivate the virus and result in perpetuation of the symptoms of fibromyalgia. Effectively suppressing latent viruses may significantly improve the pain and related symptoms of FM."
....
"Compared to placebo, the relatively high completion rate, improved pain scores and the low rate of discontinuation because of adverse events are consistent with a well-tolerated and effective therapy," Dr. Clauw said.
About IMC-1
IMC-1 is a novel combination oral medicine designed to treat HSV-1, a condition that may be one of the underlying causes of fibromyalgia syndrome. IMC-1 combines the anti-herpes virus nucleoside analog famciclovir with anti-herpes virus activity exhibited by the COX-2 inhibitor celecoxib.
Novel Fibromyalgia Treatment Shows Promise in Study
Moderator: Moderators
Novel Fibromyalgia Treatment Shows Promise in Study
http://www.prnewswire.com/news-releases ... 42331.html
STOP de mishandeling van ME patiënten!
Novel Fibromyalgia Treatment Shows Promise in Study
Duidelijk, Dit ook voor ME???